AR123188A1 - Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer - Google Patents
Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimerInfo
- Publication number
- AR123188A1 AR123188A1 ARP210102219A ARP210102219A AR123188A1 AR 123188 A1 AR123188 A1 AR 123188A1 AR P210102219 A ARP210102219 A AR P210102219A AR P210102219 A ARP210102219 A AR P210102219A AR 123188 A1 AR123188 A1 AR 123188A1
- Authority
- AR
- Argentina
- Prior art keywords
- peptide
- seq
- amino acids
- tau
- residues
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063062919P | 2020-08-07 | 2020-08-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123188A1 true AR123188A1 (es) | 2022-11-09 |
Family
ID=80118546
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102219A AR123188A1 (es) | 2020-08-07 | 2021-08-09 | Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20250186567A1 (https=) |
| EP (1) | EP4192497A4 (https=) |
| JP (1) | JP2023536995A (https=) |
| KR (1) | KR20230080397A (https=) |
| CN (1) | CN116472055A (https=) |
| AR (1) | AR123188A1 (https=) |
| AU (1) | AU2021321549A1 (https=) |
| CA (1) | CA3188456A1 (https=) |
| IL (1) | IL300347A (https=) |
| MX (1) | MX2023001503A (https=) |
| TW (1) | TW202221017A (https=) |
| WO (1) | WO2022032166A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018308088B2 (en) | 2017-07-25 | 2025-05-29 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| AU2020214796A1 (en) | 2019-01-30 | 2021-07-29 | Truebinding, Inc. | Anti-Gal3 antibodies and uses thereof |
| WO2021236809A2 (en) * | 2020-05-19 | 2021-11-25 | Othair Prothena Limited | Multi-epitope vaccine for the treatment of alzheimer's disease |
| WO2021242776A2 (en) | 2020-05-26 | 2021-12-02 | Truebinding, Inc. | Methods of treating inflammatory diseases by blocking galectin-3 |
| IL301262A (en) * | 2020-09-18 | 2023-05-01 | Othair Prothena Ltd | Multiepitope vaccine for the treatment of alzheimer's disease |
| CN115925987A (zh) * | 2022-02-28 | 2023-04-07 | 安域生物科技(杭州)有限公司 | 基于β-淀粉样蛋白修饰的抗原多肽及其应用 |
| CU20230023A7 (es) | 2023-05-12 | 2024-12-09 | Ct Ingenieria Genetica Biotecnologia | Antígeno quimérico multiblanco para la inmunoterapia de la enfermedad de alzheimer |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208036A (en) | 1985-01-07 | 1993-05-04 | Syntex (U.S.A.) Inc. | N-(ω, (ω-1)-dialkyloxy)- and N-(ω, (ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US5283185A (en) | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| WO1994012629A1 (en) | 1992-12-02 | 1994-06-09 | Baylor College Of Medicine | Episomal vectors for gene therapy |
| AU698962B2 (en) | 1993-09-14 | 1998-11-12 | Epimmune, Inc. | Alteration of immune response using pan DR-binding peptides |
| US5505947A (en) | 1994-05-27 | 1996-04-09 | The University Of North Carolina At Chapel Hill | Attenuating mutations in Venezuelan Equine Encephalitis virus |
| US7153510B1 (en) | 1995-05-04 | 2006-12-26 | Yale University | Recombinant vesiculoviruses and their uses |
| AU753688B2 (en) | 1997-03-10 | 2002-10-24 | Ottawa Civic Loeb Research Institute | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| WO2004044195A2 (en) * | 2002-11-12 | 2004-05-27 | Risø National Laboratory | Polynucleotides encoding agmatine coumaroyltransferase (act) and uses thereof |
| KR20120017469A (ko) | 2007-01-05 | 2012-02-28 | 유니버시티 오브 취리히 | 질환 특이적 결합 분자 및 표적을 제공하는 방법 |
| ES2656442T3 (es) * | 2011-09-19 | 2018-02-27 | Axon Neuroscience Se | Terapia basada en proteínas y diagnóstico de una patología mediada por tau en la enfermedad de Alzheimer |
| CA2885924C (en) * | 2012-08-21 | 2022-12-13 | Institute For Molecular Medicine, Inc. | Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein |
| CA2902026C (en) | 2013-03-13 | 2023-08-29 | Prothena Biosciences Limited | Tau immunotherapy |
| CA3003483C (en) | 2015-11-06 | 2022-09-13 | Adjuvance Technologies, Inc. | Triterpene saponin analogues |
| EP3452507B1 (en) | 2016-05-02 | 2022-10-19 | Prothena Biosciences Limited | Tau immunotherapy |
| PE20190208A1 (es) | 2016-05-02 | 2019-02-07 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau |
| CA3022515A1 (en) | 2016-05-02 | 2017-11-09 | Prothena Biosciences Limited | Antibodies recognizing tau |
| EP3609505A4 (en) | 2017-04-13 | 2021-04-28 | Adjuvance Technologies, Inc. | TRITERPEN-SAPONIN SYNTHESIS, INTERMEDIATES AND COMBINATIONS OF ADJUVANCES |
| CN110730666A (zh) | 2017-04-25 | 2020-01-24 | 佐剂技术公司 | 三萜皂苷类似物 |
| CN110881274B (zh) | 2017-05-02 | 2024-11-15 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| WO2019079160A1 (en) | 2017-10-16 | 2019-04-25 | Adjuvance Technologies, Inc. | TRITERPENIC SAPONIN ANALOGS |
| GB201803387D0 (en) * | 2018-03-02 | 2018-04-18 | One Health Ventures Ltd | Disease detection |
| CN109022460B (zh) * | 2018-08-31 | 2021-05-28 | 西藏自治区农牧科学院农业研究所 | 一种bahd酰基转移酶基因及其用途 |
-
2021
- 2021-08-06 KR KR1020237007790A patent/KR20230080397A/ko active Pending
- 2021-08-06 JP JP2023507949A patent/JP2023536995A/ja active Pending
- 2021-08-06 US US18/020,034 patent/US20250186567A1/en active Pending
- 2021-08-06 EP EP21853506.0A patent/EP4192497A4/en active Pending
- 2021-08-06 WO PCT/US2021/045062 patent/WO2022032166A1/en not_active Ceased
- 2021-08-06 AU AU2021321549A patent/AU2021321549A1/en active Pending
- 2021-08-06 CA CA3188456A patent/CA3188456A1/en active Pending
- 2021-08-06 CN CN202180067903.XA patent/CN116472055A/zh active Pending
- 2021-08-06 MX MX2023001503A patent/MX2023001503A/es unknown
- 2021-08-06 IL IL300347A patent/IL300347A/en unknown
- 2021-08-09 TW TW110129345A patent/TW202221017A/zh unknown
- 2021-08-09 AR ARP210102219A patent/AR123188A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116472055A (zh) | 2023-07-21 |
| IL300347A (en) | 2023-04-01 |
| US20250186567A1 (en) | 2025-06-12 |
| WO2022032166A1 (en) | 2022-02-10 |
| AU2021321549A1 (en) | 2023-03-09 |
| JP2023536995A (ja) | 2023-08-30 |
| TW202221017A (zh) | 2022-06-01 |
| MX2023001503A (es) | 2023-03-08 |
| EP4192497A1 (en) | 2023-06-14 |
| CA3188456A1 (en) | 2022-02-10 |
| EP4192497A4 (en) | 2024-08-21 |
| KR20230080397A (ko) | 2023-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR123188A1 (es) | Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer | |
| CL2025000674A1 (es) | Vacuna multiepítopo para el tratamiento de la enfermedad de alzheimer | |
| AR122127A1 (es) | VACUNA DE b-AMILOIDE PARA EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER | |
| Jeong et al. | Physiological roles of monomeric amyloid-β and implications for Alzheimer’s disease therapeutics | |
| CO2021000326A2 (es) | Composiciones y métodos para aumentar o mejorar la transducción de vectores de terapia genética y para eliminar o reducir las inmunoglobulinas | |
| MX2023001501A (es) | Vacuna tau para tratamiento de enfermedad de alzheimer. | |
| CN110312520B (zh) | 神经疾病的治疗 | |
| EA200901459A1 (ru) | Реконструированные поверхностно-активные вещества, имеющие улучшенные свойства | |
| DE69931793D1 (de) | Verfahren für die behandlung der multiplen sklerose mittels peptidanalogen des menschlichen basischen myelinproteins | |
| HRP20120206T4 (hr) | Cjepivo koje sadrži amb a 1 peptide za uporabu u lijeäśenju alergije na ambroziju | |
| EA202190310A1 (ru) | Белок для лечения воспалительных заболеваний | |
| PE20231076A1 (es) | Anticuerpos anti-pd-1 | |
| MX2023003007A (es) | Vacuna de sinucleina alfa para el tratamiento de sinucleinopatias. | |
| Rami et al. | β2-Adrenergic receptor responsiveness of the calpain–calpastatin system and attenuation of neuronal death in rat hippocampus after transient global ischemia | |
| CA3185884A1 (en) | Pharmaceutical composition for preventing or treating a periodontal disease or dislocated traumatic tooth | |
| CN104277092B (zh) | 用于预防和/或治疗老年性痴呆的β片层阻断肽 | |
| JP2016539911A5 (https=) | ||
| PE20211772A1 (es) | Inmunoterapia con peptidos restringidos a b 08 y una combinacion de peptidos contra el cancer y metodos relacionados | |
| MX2022009842A (es) | Inmunogenos peptidicos dirigidos al polipeptido amiloide de los islotes (iapp) y formulaciones de los mismos para la prevencion y el tratamiento de trastornos relacionados con el iapp agregado. | |
| AR122126A1 (es) | Vacuna multiepítopo para el tratamiento de la enfermedad de alzheimer | |
| US20230181692A1 (en) | Compositions for use in the treatment of neurological disease | |
| Tsukie et al. | Decreased amount of collagen in the skin of amyotrophic lateral sclerosis in the Kii peninsula of Japan | |
| EP4461303A3 (en) | Methods and compositions for treating inflammatory conditions | |
| CL2022001355A1 (es) | Uso de un anticuerpo inhibidor de masp-2, o un fragmento del mismo, para el tratamiento del síndrome de neumonía idiopática posterior a un trasplante de células madres hematopoyéticas (hsct-ips). | |
| WO2021100041A1 (en) | Treating alzheimer's disease |